281 related articles for article (PubMed ID: 28125906)
1. Difluoromethylornithine in cancer: new advances.
Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
[TBL] [Abstract][Full Text] [Related]
2. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
3. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
[TBL] [Abstract][Full Text] [Related]
4. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
[TBL] [Abstract][Full Text] [Related]
5. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
Kadmon D
J Cell Biochem Suppl; 1992; 16H():122-7. PubMed ID: 1289667
[TBL] [Abstract][Full Text] [Related]
8. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.
Ignatenko NA; Zhang H; Watts GS; Skovan BA; Stringer DE; Gerner EW
Mol Carcinog; 2004 Apr; 39(4):221-33. PubMed ID: 15057874
[TBL] [Abstract][Full Text] [Related]
9. alpha-Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo-prevention.
Smith KJ; Skelton H
Int J Dermatol; 2006 Apr; 45(4):337-44. PubMed ID: 16650154
[No Abstract] [Full Text] [Related]
10. alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model.
Takahashi Y; Mai M; Nishioka K
Int J Cancer; 2000 Jan; 85(2):243-7. PubMed ID: 10629084
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo.
Saydjari R; Alexander RW; Upp JR; Barranco SC; Townsend CM; Thompson JC
Int J Cancer; 1991 Jan; 47(1):44-8. PubMed ID: 1985877
[TBL] [Abstract][Full Text] [Related]
12. Polyamines and cancer: old molecules, new understanding.
Gerner EW; Meyskens FL
Nat Rev Cancer; 2004 Oct; 4(10):781-92. PubMed ID: 15510159
[TBL] [Abstract][Full Text] [Related]
13. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
14. Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases.
Somani RR; Rai PR; Kandpile PS
Mini Rev Med Chem; 2018; 18(12):1008-1021. PubMed ID: 28971766
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential.
Shantz LM; Levin VA
Amino Acids; 2007 Aug; 33(2):213-23. PubMed ID: 17443268
[TBL] [Abstract][Full Text] [Related]
16. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
17. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
18. The chemotherapeutic potential of polyamine antimetabolites.
Kingsnorth AN
Ann R Coll Surg Engl; 1986 Mar; 68(2):76-81. PubMed ID: 3082276
[TBL] [Abstract][Full Text] [Related]
19. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.
Ye C; Geng Z; Dominguez D; Chen S; Fan J; Qin L; Long A; Zhang Y; Kuzel TM; Zhang B
J Immunol; 2016 Jan; 196(2):915-23. PubMed ID: 26663722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
